Home › Research › Lewy body dementia
The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis
Beele, P.; Veldink, J.; van Rheenen, W.. medRxiv (preprint), 2026-09-22
Topic: Brain proteins, microglia and lab models
Plain-language summary
Simulation results were benchmarked against real-world population estimates, over a wide range of demographic and genetic parameters.
What this study adds
Evidence grade: Low
This study used simulation to examine how family history can help distinguish inherited from non-inherited forms of ALS, not Alzheimer's disease. Reported effect size: 16.4%; 31.1%; 10.0%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Beele, P., Veldink, J., & van Rheenen, W. (2026). The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis. medRxiv (preprint). https://doi.org/10.64898/2026.09.16.26362994
Vancouver
Beele P, Veldink J, van Rheenen W. The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis. medRxiv (preprint). 2026. doi:10.64898/2026.09.16.26362994.
BibTeX
@article{beele2026-11d44251,
author = {Beele, P. and Veldink, J. and van Rheenen, W.},
title = {{The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.09.16.26362994},
url = {https://doi.org/10.64898/2026.09.16.26362994}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Simulation results were benchmarked against real-world population estimates, over a wide range of demographic and genetic parameters.
Why it matters
This study used simulation to examine how family history can help distinguish inherited from non-inherited forms of ALS, not Alzheimer's disease. It has no direct implications for treating, curing, or preventing Alzheimer's disease.
Study details
- Effect size16.4%; 31.1%; 10.0%
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 22 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 21 of the 94 points we could judge it on, which is 22 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Wouter van Rheenen: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Utrecht University: institution h-index 1,157 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 21 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 21 of the 94 points we could judge it on is 22 out of 100. |
| Total | 22 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Lewy body dementia from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.